Table 3.

Biologics and other immunomodulatory therapies reported in the treatment of HS

TNF-α inhibitors	Adalimumab*10,12,14–16,23–27 Infliximab9,31,32 Etanercept51 Golimumab53,54 Certolizumab56
IL-1 inhibitors	Anakinra58,60,103 Canakinumab62,63 Bermekimab66 MEDI896870
IL-12/-23 inhibitors	Ustekinumab72
IL-17 inhibitors	Secukinumab74-76 CJM11279 Bimekizumab82
IL-23 inhibitors	Guselkumab84-86
Selective PDE-4 inhibitors	Apremilast89,90,104
Complement C5a inhibitors	IFX-191–93
CD-11a inhibitors	Efalizumab**105
CD-20 inhibitors	Rituximab95
JAK-1 inhibitors	INCB05470796,97

Notes: ^aFDA-approved for treatment of HS

^bNo longer available, and thus excluded from further review.

Abbreviation: HS, hidradenitis suppurativa.